Body composition as a predictor of toxicity after treatment with eribulin for advanced soft tissue sarcoma.
Adult
Aged
Antineoplastic Agents
/ adverse effects
Body Composition
Child
Female
Furans
/ adverse effects
Humans
Ketones
/ adverse effects
Male
Middle Aged
Quality of Life
Retrospective Studies
Risk Factors
Sarcoma
/ drug therapy
Soft Tissue Neoplasms
/ drug therapy
Tomography, X-Ray Computed
Treatment Outcome
Advanced soft tissue sarcoma
Body composition metrics
Eribulin
Toxicity
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
18
09
2018
accepted:
15
11
2018
pubmed:
23
11
2018
medline:
14
5
2019
entrez:
23
11
2018
Statut:
ppublish
Résumé
Despite the clinical benefits of eribulin on overall survival of advanced soft tissue sarcoma (STS) patients, treatment-related toxicity reduces their QOL. Body composition metrics (BCMs) are associated with poor outcome and drug toxicities in several cancers. This study investigated whether BCMs could predict drug toxicity occurrence in advanced STS patients treated with eribulin. This study included 23 advanced STS patients treated with eribulin between March 2016 and April 2018. BCMs were evaluated using a CT scan obtained within 1 month before or after treatment initiation. The relationship of BCMs and other clinical factors was evaluated and CART analysis used to develop classification models for risk groups of drug toxicity. Sixteen patients (69.6%) experienced any grade 3/4 toxicity. Eleven patients (47.8%) developed G4 hematologic toxicity, which was significantly higher in those with low skeletal muscle gauge (SMG) (P = 0.02) and low pretreatment neutrophil count (P = 0.0002). Six patients (26.1%) had grade 3/4 non-hematologic toxicity, and was higher in those with low SMG (P = 0.004), and low serum albumin level (P = 0.02). Five patients with high BMI (P = 0.03) experienced febrile neutropenia (FN) and low pretreatment neutrophil count (P = 0.02). CART analysis classified three risk groups, and area under the receiver operating characteristic curve (AUROCC) was 0.92, 0.88, 0.92 in G4 hematologic AE, G3/4 non-hematologic AE, FN, respectively. SMG is a significant predictive factor of eribulin drug toxicity in advanced STS patients. Risk classification of drug toxicity through combining predictive factors, could improve the therapeutic strategy used in chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the clinical benefits of eribulin on overall survival of advanced soft tissue sarcoma (STS) patients, treatment-related toxicity reduces their QOL. Body composition metrics (BCMs) are associated with poor outcome and drug toxicities in several cancers. This study investigated whether BCMs could predict drug toxicity occurrence in advanced STS patients treated with eribulin.
METHODS
METHODS
This study included 23 advanced STS patients treated with eribulin between March 2016 and April 2018. BCMs were evaluated using a CT scan obtained within 1 month before or after treatment initiation. The relationship of BCMs and other clinical factors was evaluated and CART analysis used to develop classification models for risk groups of drug toxicity.
RESULTS
RESULTS
Sixteen patients (69.6%) experienced any grade 3/4 toxicity. Eleven patients (47.8%) developed G4 hematologic toxicity, which was significantly higher in those with low skeletal muscle gauge (SMG) (P = 0.02) and low pretreatment neutrophil count (P = 0.0002). Six patients (26.1%) had grade 3/4 non-hematologic toxicity, and was higher in those with low SMG (P = 0.004), and low serum albumin level (P = 0.02). Five patients with high BMI (P = 0.03) experienced febrile neutropenia (FN) and low pretreatment neutrophil count (P = 0.02). CART analysis classified three risk groups, and area under the receiver operating characteristic curve (AUROCC) was 0.92, 0.88, 0.92 in G4 hematologic AE, G3/4 non-hematologic AE, FN, respectively.
CONCLUSIONS
CONCLUSIONS
SMG is a significant predictive factor of eribulin drug toxicity in advanced STS patients. Risk classification of drug toxicity through combining predictive factors, could improve the therapeutic strategy used in chemotherapy.
Identifiants
pubmed: 30465138
doi: 10.1007/s10147-018-1370-8
pii: 10.1007/s10147-018-1370-8
doi:
Substances chimiques
Antineoplastic Agents
0
Furans
0
Ketones
0
eribulin
LR24G6354G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-444Références
J Clin Oncol. 2004 Nov 1;22(21):4302-11
pubmed: 15381684
N Engl J Med. 2005 Aug 18;353(7):701-11
pubmed: 16107623
Lancet Oncol. 2005 Sep;6(9):669-77
pubmed: 16129367
J Clin Oncol. 2007 Oct 20;25(30):4821-8
pubmed: 17947731
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Eur J Cancer. 2009 Jul;45(10):1757-63
pubmed: 19217278
Clin Cancer Res. 2009 Apr 15;15(8):2920-6
pubmed: 19351764
J Clin Oncol. 2009 Sep 1;27(25):4188-96
pubmed: 19652065
Biochemistry. 2010 Feb 16;49(6):1331-7
pubmed: 20030375
Ann Oncol. 2010 Aug;21(8):1594-8
pubmed: 20089558
Cancer Res. 2011 Jan 15;71(2):496-505
pubmed: 21127197
Lancet Oncol. 2011 Oct;12(11):1045-52
pubmed: 21937277
Cancer. 2012 Nov 1;118(21):5339-48
pubmed: 22517534
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Eur J Cancer. 2013 Feb;49(3):684-95
pubmed: 23079473
Br J Cancer. 2014 Mar 18;110(6):1497-505
pubmed: 24569463
Asian Pac J Cancer Prev. 2014;15(8):3443-6
pubmed: 24870736
Cancer Sci. 2014 Oct;105(10):1334-42
pubmed: 25060424
Eur J Surg Oncol. 2015 Mar;41(3):333-8
pubmed: 25498359
Lancet Oncol. 2015 Apr;16(4):406-16
pubmed: 25795406
Clin Cancer Res. 2015 Jun 1;21(11):2445-52
pubmed: 25838395
Semin Cell Dev Biol. 2016 Jun;54:2-10
pubmed: 26343952
J Surg Oncol. 2016 Mar;113(3):333-8
pubmed: 26662660
Lancet. 2016 Apr 16;387(10028):1629-37
pubmed: 26874885
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
Clin Cancer Res. 2017 Jul 15;23(14):3537-3543
pubmed: 28143874
Jpn J Clin Oncol. 2017 Feb 1;47(2):137-144
pubmed: 28173193
Int J Urol. 2017 Jun;24(6):449-453
pubmed: 28421640
Cancer Sci. 2018 May;109(5):1570-1575
pubmed: 29493842
Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9
pubmed: 29506228
Oncology. 2018;95(1):1-7
pubmed: 29510410
Urol J. 2018 Jul 10;15(4):168-172
pubmed: 29681054
Support Care Cancer. 2018 Nov;26(11):3691-3699
pubmed: 29736867
Anticancer Res. 2018 Oct;38(10):5853-5858
pubmed: 30275210